MPC1 and cancer: Reduction in MPC1 levels and activity contribute to cancer progression by promoting epithelial to mesenchymal transition (EMT) [38] or increasing resistance to chemotherapy [39], and lower MPC1 expression is associated with the PDAC glycolytic subtype, a marker of poor prognosis [22].